Sunshine Biopharma (SBFM) Operating Expenses (2010 - 2026)

Sunshine Biopharma's Operating Expenses history runs 16 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• Quarterly Operating Expenses fell 13.3% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.3 million (up 7.26% YoY) and the FY2025 annual result came in at $23.0 million, up 11.82% from the prior year.
• Operating Expenses was $4.5 million for Q1 2026 at Sunshine Biopharma, down from $6.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.9 million in Q4 2022 and bottomed at $817363.0 in Q2 2022.
• A 5-year average of $5.5 million and a median of $4.8 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 6208.37% — and 2023, when it sank 78.74%.
• Sunshine Biopharma's Operating Expenses stood at $24.9 million in 2022, then sank by 78.74% to $5.3 million in 2023, then increased by 16.9% to $6.2 million in 2024, then advanced by 3.62% to $6.4 million in 2025, then slumped by 30.11% to $4.5 million in 2026.
• Business Quant data shows SBFM's Operating Expenses at $4.5 million in Q1 2026, $6.4 million in Q4 2025, and $4.9 million in Q3 2025.